




SOLVE
ON.

Third Quarter 2026 Financial Results & Business Update

OCTOBER 29, 2026



Agenda

01

Introduction

Alexis Smith | *VP, Investor Relations*

02

Business Performance

Bill Meury | *Chief Executive Officer*

03

R&D Highlights

Pablo Cagnoni, M.D. | *President,
Global Head of R&D*

04

Financial Results

Suky Upadhyay | *EVP,
Chief Financial Officer*

05

Closing Remarks

Bill Meury | *Chief Executive Officer*

06

Q&A

Steven Stein, M.D. | *EVP, Chief Medical Officer
and Head of Late-Stage Development*

Dave Gardner | *EVP, Chief Strategy Officer*

Mohamed Issa, Pharm.D. | *EVP,
Head of US Commercial*

Forward looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Incyte's expected financial and operational performance; Incyte's updated 2026 full year financial guidance; expectations regarding the impact of Incyte's agreement with CMS; Incyte's ability to deliver sustained long-term growth and create long-term value for patients and shareholders; the strength and growth of Incyte's core business and marketed products; expectations regarding the future growth and potential size of Incyte's core business, including the core business excluding Jakafi, and the potential contribution of Incyte's pipeline to future revenue growth; the potential and progress of programs in Incyte's pipeline, including their potential to provide significant future growth opportunities; expectations regarding the initiation, timing, progress, design, scope and results of clinical trials, proof-of-concept programs, combination studies and registrational development programs, and anticipated data readouts, including for Niktimvo (axatilimab), INCA033989 (mutCALR), INCA041798, INCA035784, latarcibart, INCB161734 (KRAS G12D), INCA33890 (TGFβR2×PD-1), INCB123667 (CDK2), Opzelura (ruxolitinib) cream and povorcitinib; expectations regarding regulatory submissions, regulatory decisions, approvals and commercial launches, including for Monjuvi in newly diagnosed DLBCL and povorcitinib in hidradenitis suppurativa and nonsegmental vitiligo; expectations regarding the Vega Therapeutics acquisition and the potential benefits of latarcibart; Incyte's goals of building diversified growth pipelines in hematology, oncology, and inflammation and autoimmunity and establishing long-term leadership in myeloproliferative neoplasms and gastrointestinal oncology; expectations regarding Incyte's partnerships and collaborations; and Incyte's aspirations and goals.

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte's products; Incyte's ability to achieve commercial success for its marketed products and product candidates, if approved; Incyte's ability to obtain and maintain protection of intellectual property for its products and technology; Incyte's reliance on third parties and partners; the acceptance of Incyte's products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte's products; the impact of agreements or arrangements with governmental authorities relating to the pricing, reimbursement or coverage of Incyte's products; and those risks and uncertainties discussed in greater detail in Incyte's reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.



Opening Remarks & Business Progress

Bill Meury | *Chief Executive Officer*

Strategy for the transition and recovery

Core business

The foundation

Scale beyond Jakafi to navigate the 2029 transition and fund R&D

Late-stage pipeline

The next phase of growth

Layer on top of the core business to drive growth post the transition

Opportunity to build a significantly larger company over the next decade

Potential first-in-class assets in late-stage development

INCB161734

KRAS G12D inhibitor

Pancreatic & colorectal cancer

~74k patients with KRAS G12D-mutated disease across PDAC and CRC^{1,3-4}

INCA033989

mutCALR antibody

Myeloproliferative neoplasms

~30k patients with CALR-mutated ET and MF^{2,5}

LATARCIBART

Protein S modulator

VWD and other bleeding disorders

~135k diagnosed VWD patients^{2,6}

POVORCITINIB

JAK1 selective inhibitor

HS, prurigo nodularis and vitiligo

~700k HS, PN and vitiligo patients^{2,7-9}

INCA33890

TGF β R2 $\times$ PD-1 bispecific

Colorectal cancer

~200k patients with metastatic MSS CRC^{1,10}

INCB123667

CDK2 inhibitor

Ovarian cancer (CCNE1+)

~10k patients with CCNE1+ ovarian cancer^{1,11}

Strong 3Q results and execution across the pipeline

Delivering on core business

Total net sales
\$1.32B (+14% YoY)¹

Core business (ex-Jakafi)
\$490M (+37% YoY)¹

Regulatory and launch progress

Approval and launch of
Opzelura in mAD in Europe

Two near-term potential approvals and launches
(Monjuvi, povorcitinib)²

Advancing late-stage pipeline


Expanding GI scope for '734
and '890 across settings and
tumor types

Phase 3 studies underway or
planned for '989 in 2L ET & 2L MF
and **latarcibart** in VWD

Total revenue reached \$1.56B, increasing 14% versus prior year

\$1.56B 3Q26 total revenue
(+14% vs. 3Q25)¹


- **\$1.32B** total net sales
- **\$241M** royalty & contract revenue



¹Reflects net sales, royalty revenue, and milestone and contract revenue.

Total net sales growth of 14% driven by strong performance across core business

\$1.32B 3Q26 total net sales (+14% vs. 3Q25)¹



¹Reflects net sales, excluding royalty revenue and milestone and contract revenue.

Jakafi demand and early XR adoption support franchise growth

\$827M 3Q26 net sales (+4% vs. 3Q25)¹


- **\$15M 3Q26** Jakafi XR™ net sales

Demand **+12%** vs. 3Q25

Broad based growth across **PV, MF and GVHD**

XR uptake reflects both **new and existing patients**

Channel inventory within **normal range**




Core business (ex-Jakafi) continues to grow, increasing 37% YoY

\$490M 3Q26 net sales (+37% vs. 3Q25)¹

Core business (ex-Jakafi) now represents **>35%** of total net sales for the quarter

Potential to reach **\$3–\$4B by 2030**




¹Reflects net sales, excluding royalty revenue and milestone and contract revenue. JAKAFI, OPZELURA, MONJUVI/MINJUVI, PEMAZYRE and ZYNYZ are our registered trademarks; NIKTIMVO and JAKAFI XR are our trademarks.

Strong demand across indications and geographies drives Opzelura momentum

\$255M 3Q26 net sales (+36% vs. 3Q25)¹

- U.S. net sales of **\$208M** (+45% vs. 3Q25)
 - **+24%** TRx growth
- Ex-U.S. net sales of **\$47M** (+5% vs. 3Q25)


Growth drivers: expanded sales force, specific NP/PA engagement, and improved access



Hematology and Oncology portfolio growing 38% versus prior year

\$235M 3Q26 net sales (+38% vs. 3Q25)¹ driven by:

- **Niktimvo** net sales of **\$67M** (+47%)²
- **Zynyz** net sales of **\$58M** (+157%)²
- **Monjuvi/Minjuvi** net sales of **\$55M** (+30%)²





Research & Development Highlights

Pablo Cagnoni, M.D. | *President, Global Head of R&D*

Advancing a novel late-stage pipeline to drive long-term growth

Hematology

INCA033989

mutCALR mAb — 2L ET & 2L MF

Latacibart

Protein S modulator — VWD

Axatilimab

CSF-1R — 1L chronic GVHD
(+steroids, +ruxolitinib)

Oncology

INCB161734

KRAS G12Di — 1L PDAC,
adjuvant PDAC, 2L/3L CRC

INCA33890

TGFβR2×PD-1 — 1L MSS CRC

INCB123667

CDK2i — 1L maintenance ovarian

IAI

Ruxolitinib cream

JAK1/2 — mild HS

Povorcitinib

JAK1 — moderate-severe PN

10+

Ongoing and
planned pivotal
trials by 1H27

6

Potential first-in-
class assets

5

Pivotal and POC
readouts by YE26

Building a leading mutation-targeted CALR franchise



'989

mutCALR mAb

Essential Thrombocythemia

Advancing first-in-class mutation-targeted therapy in ET

- Ph. 3 EXCALIBUR-ET2 (2L ET) ongoing

Myelofibrosis

Expanding development across lines of therapy

- Ph. 3 initiation (2L MF) – 4Q26
- Ph. 1 data in 1L MF (monotherapy & + rux) – 4Q26

'798

mutCALR mAb

CALR-mutated MPNs

Advancing next generation mutCALR antibody


- Preclinical data – 4Q26
- Ph. 1 initiation – 1H27

'989: Pivotal Phase 3 in 2L MF to initiate by EOY

Key Ph. 3 trial features:

- **Population:** **Type 1 and non-Type 1** mutCALR positive MF patients previously treated with a JAK inhibitor
- **Dosing:** **750mg IV Q2W** (Type 1); **2500mg IV Q2W** (non-type 1)
- **Comparator:** Best available therapy (BAT)
- **Coprimary endpoints (Type 1):** **SVR35 and TSS50 at Week 36**
- **Key secondary endpoint (Type 1):** **Composite endpoint at Week 36¹**, integrating measures of disease burden and hematologic improvement

~10k people in the U.S. with **CALR+ MF**



~70%
of patients are Type 1²

~2/3
of people do not
respond adequately to
SOC³

20% risk of transformation to AML⁴

¹Overall response defined as meeting specific criteria of 4 endpoints including hemoglobin, platelet, blasts in peripheral blood and spleen volume parameters.

²Cabagnols X et al. Leukemia. 2015. ³Harrison c, et al. NEJM 2012 ⁴ Mesa RA, et al. Blood. 2005.

Advancing diversified late-stage hematology pipeline

Myeloproliferative Neoplasms

Advancing targeted therapies through early- and late-stage development

- '989 (mutCALR mAb)
- '798 (next generation mutCALR mAb)
- '784 (CALR x CD3 bispecific)
- '954 (JAK2V617F)

Graft-versus-host disease

Improving outcomes through earlier and combination-based interventions

Axatilimab

- Ph. 2 (+ ruxolitinib) data – 1Q27
- Ph. 3 (+ steroids) topline data – early-2028

Bleeding disorders

Potential to transform treatment of VWD with a novel, non-factor replacement approach

Latarcibart in VWD

- Ph. 1/2 OLE data – 4Q26
- Ph. 3 topline data – early-2029

'734: Expanding development across tumor types and treatment settings

1L PDAC

Antitumor activity and early durability in combination with 1L SOC

+ mFOLFIRINOX

- ORR¹: 81%; DCR: 100%
- 6-month landmark PFS: 90%

+ GemNabP

- ORR¹: 58%; DCR: 96%
- 6-month landmark PFS: 80%

Heavily-pretreated CRC

Activity with cetuximab suggests synergy with EGFR in late-line CRC

+ cetuximab

- ORR: 36%; DCR: 100%
- Median PFS: 7.2 months

2028

Phase 3 DAWN-303
topline data in 1L PDAC

1H 2027

Phase 3 DAWN-302
initiation in 2L/3L CRC

2027

Phase 3 adjuvant
PDAC initiation

'734: Expansion across tumors and lines

	ADJUVANT	1L	2L+	
PDAC	CTx +/- <i>Phase 3 in 2027</i>	CTx (mFFX / GnP) +/- <i>Phase 3 DAWN-303 ongoing</i>	+ SNV1521 (PARP1i)	+ navlimetostat (PRMT5i)
CRC	—	<div>+ CTx + cetuximab (FOLFOX / FOLFIRI)</div> <div>+ CTx + petosemtamab (EGFR x LGR5 bsAb)</div>	+ SNV1521 (PARP1i)	+ cetuximab <i>2L/3L Phase 3 DAWN-302 in 1H 2027</i>
NSCLC and other 12D-mutated tumors	—	—	Monotherapy	

■ Represents ongoing POC or Phase 3 programs.

'890: Potential immunotherapy backbone in MSS CRC

1L metastatic MSS CRC

Encouraging antitumor activity and early durability

'890 + FOLFOX + bevacizumab

- ORR: 71%
- DCR: 100%
- 6-month landmark PFS: 81%

Efficacy in key populations

- Liver metastases ORR: 83%
- Peritoneal metastases ORR: 62%
- PD-L1 TAP >1% ORR: 81%

2029

Phase 3 NEXERA-303
topline data in 1L MSS
CRC

2H 2026

Initiated POC adjuvant
study in ctDNA-positive
disease following surgery

'890: A novel immunotherapy backbone in CRC

	ADJUVANT	1L	2L+
CRC	Monotherapy <i>ctDNA+ post adjuvant chemo</i>	+ FOLFOX + bevacizumab <i>MSS · Phase 3 NEXERA-303</i>	<div>+ muzastotug (next-gen CTLA-4)</div> <div>+ bevacizumab</div>
Ovarian	—	+ CTx +/- bevacizumab	+ ADC
HNSCC	—	+ EGFR Ab	—
NSCLC	—	+ CTx	—

■ Represents ongoing POC or Phase 3 programs.

Expanding solid tumor pipeline with focus in GI



'890

TGFβR2×PD-1 bispecific

MSS colorectal cancer

Large, underserved population with no approved IO options

- Ph. 3 NEXERA-303 (1L MSS CRC) data – 2029
- Ph. 2 NEXERA-204 (adjuvant ctDNA+) ongoing



'734

KRAS G12D inhibitor

KRAS G12D mutated cancers

Targeting a large clinical need across KRAS G12D-driven GI cancers

- Ph. 3 DAWN-303 (1L PDAC) data – 2028
- Ph. 3 DAWN-302 (2L/3L CRC) initiation – 1H 2027
- Ph. 3 trial initiation in adjuvant PDAC – 2027



'667

CDK2 inhibitor

Ovarian cancer (CCNE1+)

Addresses genetically defined, high-risk ovarian cancer subset

- Ph. 2 MAESTRA-1 trial in PROC ongoing
- Ph. 3 MAESTRA-3 (1L maintenance OC) initiation – 4Q26

IAI: Multiple near-term clinical & regulatory milestones



Ruxolitinib Cream

JAK1/2 small molecule

Hidradenitis Suppurativa

Potential third indication to expand addressable market

- Ph. 3 studies ongoing (TRuE-HS1; TRuE-HS2)
- Ph. 3 topline data – 4Q26



Povorcitinib

JAK1 small molecule

Hidradenitis Suppurativa

Anchor indication with large commercial opportunity

- Positive CHMP opinion for moderate to severe HS in 3Q
- Anticipated EU/US approval & launch – 4Q26/1Q27¹

Nonsegmental Vitiligo

Broadens franchise → expansion to moderate-severe

- Positive Ph. 3 data (STOP-V1; STOP-V2) in 2Q
- Planned regulatory submissions – 1H27

Prurigo Nodularis

JAK dependent immuno-derm disease

- Ph. 3 studies ongoing (STOP-PN1; STOP-PN2)
- Ph. 3 topline data – 4Q26

Late-stage pipeline positioned to deliver meaningful topline growth through 2030s

'734

KRAS G12D inhibitor

- Ph. 3 1L PDAC topline data – 2028
- Ph. 3 adjuvant PDAC and 2L/3L CRC study initiations – 2027

'989

mutCALR antibody

- Ph. 3 2L ET study ongoing
- Ph. 3 2L MF study initiation – 4Q26

Latacibart

Protein S modulator

- Ph. 3 VWD topline data – early-2029

Povorcitinib

JAK1 selective inhibitor

- Ph. 3 PN topline data – 4Q26
- Anticipated PDUFA/launch (HS) – 1Q27
- Planned submissions (vitiligo) – 1H27

'890

TGFβR2×PD-1 bispecific

- Ph. 3 1L MSS CRC topline data – 2029

'667

CDK2 inhibitor

- Ph. 3 1L maintenance OC initiation – 4Q26



Financial Results

Suky Upadhyay | *EVP, Chief Financial Officer*

Non-GAAP adjustments

- Management has chosen to present financial highlights for the quarter and year-to-date periods ended September 30, 2026, and 2025 on both a GAAP and Non-GAAP basis in the belief that this Non-GAAP information is useful for investors.
- Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes. These metrics are also used to manage the Company's business and monitor performance. The Company adjusts, where appropriate, for expenses in order to reflect the Company's core operations.
- The Company believes these adjustments are useful to investors by providing an enhanced understanding of the financial performance of the Company's core operations. The metrics have been adopted to align the Company with disclosures provided by industry peers.
- As changes in exchange rates are an important factor in understanding period-to-period comparisons, Management believes the presentation of certain revenue results on a constant currency basis in addition to reported results helps improve investors' ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period over period. The Company calculates constant currency by calculating current year results using prior year foreign currency exchange rates and generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Financial highlights – revenues

\$ MILLIONS	Q3 2026	Q3 2025	YOY CHANGE		YTD 2026	YTD 2025	YOY CHANGE	
	GAAP	GAAP	AS REPORTED	CONSTANT CURRENCY	GAAP	GAAP	AS REPORTED	CONSTANT CURRENCY
Net sales	1,316	1,150	14%	15%	3,909	3,132	25%	25%
Jakafi	827	791	4%	NA	2,401	2,264	6%	NA
Opzelura ¹	255	188	36%	36%	848	471	80%	79%
Hematology and Oncology ²	235	171	38%	38%	661	396	67%	65%
Royalties	191	171	12%		517	453	14%	
Jakavi	132	126	5%	6%	362	328	11%	7%
Olumiant	39	37	5%	8%	114	101	12%	12%
Tabrecta	7	7	5%	NA	20	20	(0.3)%	NA
Other	13	2	582%	NA	21	4	382%	NA
Total product & royalty revenues	1,507	1,321	14%		4,426	3,584	23%	
Milestone and contract revenue	50	45	11%		78	50	56%	
Total revenues	1,557	1,366	14%		4,504	3,634	24%	

NA, not applicable.

For all periods there were no adjustments between GAAP and Non-GAAP revenues. Totals may not add due to rounding.

¹Includes \$246 million impact from agreement with CMS during the second quarter of 2026 in relation to line extension. ²Pemazyre in the U.S., Canada, Europe, Japan, Asia Pacific (APAC), Middle East and Africa (MEA) and Latin America (LatAm); Niktimvo and Monjuvi in the U.S.; Zynyz in the U.S. and Europe; Iclusig in Europe and MEA; and Minjuvi in Canada, Europe, APAC, MEA and LatAm.

Financial highlights – costs, expenses and other

	Q3 2026	Q3 2025	YOY CHANGE	YTD 2026	YTD 2025	YOY CHANGE
\$ MILLIONS	GAAP	GAAP		GAAP	GAAP	
COGS	109	99	10%	318	251	27%
As a percentage of net sales	8.3%	8.6%		8.1%	8.0%	
Contract dispute settlement	—	—	NM	—	(242)	NM
R&D	1,792	507	254%²	2,825	1,439	96%
R&D – ongoing	552	506	9%	1,573	1,408	12%
R&D – upfront and milestones & acquisition-related costs ¹	1,240	0.1	NM	1,252	30	4,038%
SG&A	364	329	11%	1,044	986	6%
Asset impairment and related disposal costs	—	—	NM	23	—	NM
Loss on change in fair value of acquisition - related contingent consideration	1	(12)	NM	3	22	(85)%
Total costs, expenses and other	2,266	922	146%²	4,213	2,455	72%

NM, not meaningful. Totals may not add due to rounding.

¹Includes \$1,237.3 million and \$1,249.9 million of upfront and milestone payments, inclusive of the Vega acquisition, for the three and nine months ended September 30, 2026, respectively, and \$0.1 million and \$28.2 million of upfront and milestone payments for the three and nine months ended September 30, 2025, respectively. Includes \$2.6 million of Vega transition costs representing employee related costs to transition research and development activities and Vega acquisition related compensation expense related to retention payments, for both the three and nine months ended September 30, 2026. Includes \$2.1 million of Escient acquisition related compensation expense related to severance payments for the nine months ended September 30, 2025.

²Excluding the Vega related IPR&D expense, R&D and total operating expenses for the third quarter of 2026 grew 11% and 12%, respectively, compared to prior year period.

Full year 2026 financial guidance

	CURRENT	PREVIOUS
Total net sales	\$5,210M - \$5,300M	\$5,130M - \$5,260M
Jakafi ¹	Unchanged	\$3,220M - \$3,270M
Opzelura ²	\$1,100M - \$1,120M	\$1,050M - \$1,100M
Hematology and Oncology ³	\$890M - \$910M	\$860M - \$890M
Total R&D and SG&A operating expenses (GAAP)⁴	Unchanged	\$4,915M - \$4,995M
Total R&D and SG&A operating expenses (non-GAAP)^{4,5}	Unchanged	\$4,625M - \$4,695M

¹Includes Jakafi IR & Jakafi XR net sales. ²Includes net sales for moderate atopic dermatitis in Europe. ³Includes Pemazyre in the U.S., Canada, Europe, Japan, APAC, MEA, and LatAm; Niktimvo and Monjuvi in the U.S.; Zynyz in the U.S., Europe and Japan; Iclusig in Europe and MEA; and Minjuvi in Canada, Europe, Japan, APAC, MEA and LatAm. ⁴Includes upfront cost related to the acquisition of Vega Therapeutics which will be recognized as IPR&D expense impacting both the third quarter and full-year 2026 in addition to incremental R&D investment related to laticibart. ⁵Adjusted to exclude the estimated cost of stock-based compensation.



Q&A



SOLVE
ON.

Thank *you*



Appendix

Upcoming pipeline milestones

THERAPEUTIC	PROGRAM	INDICATION(S)	PROOF OF CONCEPT	PIVOTAL	MILESTONE/STATUS
Hematology	Axatilimab CSF-1R	1L cGvHD (+ ruxolitinib)			Ph. 2 data 1Q27
		1L cGvHD (+ steroids)			Ph. 3 data early-2028
	INCA033989 mutCALR	CALR-mutated ET (2L)			Ph. 3 trial ongoing
		CALR-mutated MF (1L)			Ph. 1 data 4Q26
		CALR-mutated MF (2L)			Ph. 3 initiation 4Q26
	INCA035784 CALRxCD3 bispecific	CALR-mutated MF, ET			Ph. 1 data 2027
Oncology	Tafasitamab CD19	DLBCL (1L)			Approval/launch 1Q27
	Latacibart Protein S modulator	VWD			Ph. 3 data early-2029
	INCB123667 CDK2	PROC			Ph. 2 trial ongoing
		Ovarian (1L maintenance)			Ph. 3 initiation 4Q26
	INCB161734 KRAS G12D	PDAC (1L)			Ph. 3 data 2028
	INCA33890 TGFβR2×PD-1 bispecific	MSS CRC (1L)			Ph. 3 data 2029
IAI	Ruxolitinib Cream JAK1/JAK2	HS (mild/moderate)			Ph. 3 data 4Q26
		HS (moderate/severe)			Approval/launch late-2026 and 1Q27 ¹
	Povorcitinib JAK1	PN (moderate/severe)			Ph. 3 data 4Q26
		Vitiligo (moderate/severe)			sNDA submission 1H27
		Asthma			Ph. 2 data 4Q26

Abbreviation directory

'667	INCB123667	ET	Essential thrombocythemia	MPN	Myeloproliferative neoplasms
'734	INCB161734	FDA	U.S. Food and Drug Administration	MSS	Microsatellite stable
'890	INCA33890	FOLFIRI	Folinic acid (leucovorin), fluorouracil and irinotecan	OC	Ovarian cancer
'989	INCA033989	FOLFOX	Leucovorin, fluorouracil and oxaliplatin	OLE	Open label extension
1L	First-line	GI	Gastrointestinal	ORR	Objective response rate
2L	Second-line	GnP	Gemcitabine, nab-paclitaxel	PDAC	Pancreatic ductal adenocarcinoma
AML	Acute myeloid leukemia	GVHD	Graft-versus-host disease	PFS	Progression-free survival
bev	bevacizumab	HS	Hidradenitis suppurativa	PN	Prurigo nodularis
bsAb	Bispecific antibody	IAI	Inflammation & Autoimmunity	POC	Proof of concept
ctDNA+	Circulating tumor DNA positive	IO	Immuno-oncology	PROC	Platinum-resistant ovarian cancer
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4	IV	Intravenous	PV	Polycythemia vera
CTx	Chemotherapy	JAK	Janus kinase	Q2W	Every two weeks
CHMP	Committee for Medicinal Products for Human Use	KRAS	Kirsten rat sarcoma	SVR35	spleen volume reduction of 35% or greater from baseline
CCNE+	Cyclin E1 positive	LGR5	Leucine-rich repeat-containing G-protein coupled receptor 5	TRx	Total prescription
CRC	Colorectal cancer	mAb	Monoclonal antibody	TSS50	a ≥50% reduction in Total Symptom Score
DCR	Disease control rate	mAD	Moderate atopic dermatitis	VWD	Von Willebrand disease
EGFR	Epidermal growth factor receptor	MF	Myelofibrosis	YoY	Year-over-year
ESMO	European Society for Medical Oncology	mFFX	Modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, oxaliplatin	XR	Extended-release